January 7, 2020
Ono Pharmaceutical and Seikagaku said on January 6 that they have filed a new drug application (NDA) in Japan for their investigational agent ONO-5704/SI-613 for the treatment of osteoarthritis (knee joint, hip joint, and ankle joint). The filing rides on...read more